Smoking Attributable Risk in Multiple Sclerosis.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 20 12 2021
accepted: 14 02 2022
entrez: 21 3 2022
pubmed: 22 3 2022
medline: 3 5 2022
Statut: epublish

Résumé

Tobacco smoke is an important modifiable environmental risk factor for multiple sclerosis (MS) risk. The population attributable fraction (AF) of MS due to smoking can be used to assess the contribution of smoking to the risk of MS development. We conducted a matched case-control study, including individuals with MS and population-based controls. Overall, sex- and genetic risk score-stratified AF due to smoking were calculated by fitting logistic regression models. We included 9,419 individuals with MS and 9,419 population-based matched controls. At the time of MS onset 44.1% of persons with MS and 35.9% of controls ever regularly smoked of which 38.1% and 29.2% were still smoking. The overall AF was 13.1% (95%CI: 10.7 to 15.4). The AF was 10.6% (95%CI: 7.4 to 13.7) in females and 19.1% (95%CI: 13.1 to 25.1) in males. The AF was 0.6% (95%CI: 0.0 to 2) in ex-smokers. In those having human leucocyte antigen (HLA) and non-HLA risk scores above the median levels of controls, the AF was 11.4% (95%CI: 6.8 to 15.9) and 12% (95%CI: 7.7 to 16.3), respectively. The AF was 17.6% (95%CI: 10.2 to 24.9) and 18.6% (95%CI: 5.5 to 31.6) in those with HLA and non-HLA risk scores below the median levels in controls, respectively. We noticed a decline in AF in recent birth cohorts. This study indicates that at least 13% of cases of MS could be prevented through the avoidance of tobacco smoking. Considering the prevalence of MS, this represents a very large group of people in absolute number.

Identifiants

pubmed: 35309300
doi: 10.3389/fimmu.2022.840158
pmc: PMC8927036
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

840158

Informations de copyright

Copyright © 2022 Manouchehrinia, Huang, Hillert, Alfredsson, Olsson, Kockum and Constantinescu.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Public Health (Oxf). 2017 Jun 1;39(2):312-320
pubmed: 27160862
Nat Rev Neurol. 2017 Jan;13(1):25-36
pubmed: 27934854
Brain. 2013 Jul;136(Pt 7):2298-304
pubmed: 23757766
Mult Scler. 2016 Jul;22(8):1021-6
pubmed: 26459151
J Neuroimmunol. 2019 Apr 15;329:24-34
pubmed: 30361070
Eur J Epidemiol. 2016 Jun;31(6):575-82
pubmed: 26992709
Acta Neurol Scand. 2015;132(199):11-9
pubmed: 26046553
Br J Cancer. 2021 Feb;124(3):658-662
pubmed: 33106583
Nicotine Tob Res. 2018 Apr 2;20(5):589-595
pubmed: 28402456
Neurology. 2020 Jun 9;94(23):e2457-e2467
pubmed: 32434867
Nat Genet. 2015 Oct;47(10):1107-1113
pubmed: 26343388
Science. 2019 Sep 27;365(6460):
pubmed: 31604244
Eur J Epidemiol. 2013 Nov;28(11):867-74
pubmed: 24146047
JAMA Neurol. 2015 Oct;72(10):1117-23
pubmed: 26348720
Int J Environ Res Public Health. 2016 Nov 09;13(11):
pubmed: 27834883

Auteurs

Ali Manouchehrinia (A)

Centre for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.

Jesse Huang (J)

Centre for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.

Jan Hillert (J)

Centre for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.

Lars Alfredsson (L)

Centre for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.

Tomas Olsson (T)

Centre for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.

Ingrid Kockum (I)

Centre for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.

Cris S Constantinescu (CS)

Department of Neurology, Cooper Neurological Institute, Camden, NJ, United States.
Section of Clinical Neurology, Academic Division of Mental Health and Clinical Neuroscience, University of Nottingham, Nottingham, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH